Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep 14;23(13):1610-1623.
doi: 10.1177/1087054718799367. Print 2019 Nov 1.

Health-Related Quality of Life and Work Productivity of Adults With ADHD: A U.K. Web-Based Cross-Sectional Survey

Alain Joseph  1 , Charlotte E Kosmas  2 , Chloe Patel  2 , Helen Doll  2 , Philip Asherson  3
Affiliations

Health-Related Quality of Life and Work Productivity of Adults With ADHD: A U.K. Web-Based Cross-Sectional Survey

Alain Joseph et al. J Atten Disord. .

Abstract

Objective: The objective of this study was to assess health-related quality of life (HRQoL) in adult ADHD.

Method: U.K. residents aged 18 to 55 years with ADHD and no major mental health comorbidities completed an online survey of disorder history, the EuroQoL 5-Dimensions 5-Level (EQ-5D-5L), and the Work Productivity and Activity Impairment Questionnaire: General Health (WPAI:GH). ADHD Rating Scale-IV (ADHD-RS-IV) score was assessed by telephone.

Results: In total, 233 participants completed the study (mean age 32.6 years; 65.2% women). Mean ( SD) ADHD-RS-IV total score, EQ-5D utility, and visual analog scale (VAS) scores were 43.5 (7.88), 0.74 (.21), and 69.8 (17.76), respectively. Mean ( SD) WPAI:GH scores indicated that health problems caused 45.7% (29.9) overall work impairment and 45.8% (28.9) impairment in regular daily activities. Greater work and activity impairment were both significantly independently associated with lower utility after adjusting for age, gender, and somatic comorbidities.

Conclusion: Adult ADHD impairs HRQoL, work productivity, and regular daily activities.

Keywords: ADHD; EQ-5D; WPAI:GH; adult; health-related quality of life.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr. Alain Joseph is a former employee of Shire and may hold stock/stock options. Dr. Charlotte E. Kosmas is an employee of ICON. Ms. Chloe Patel was an employee of ICON during the conduct of the study. Dr. Helen Doll is an employee of ICON. The King’s College London research support account for Professor Philip Asherson received honoraria for consultancy to Eli Lilly, Novartis, and Shire; educational/research awards from Eli Lilly, GW Pharmaceuticals, Novartis, Qbtech, Shire, and Vifor Pharma; and honoraria for speaking at sponsored events for Eli Lilly, Novartis, and Shire. Professor Asherson is supported by generous grants from the National Institute for Health Research Biomedical Research Centre for Mental Health at King’s College London Institute of Psychiatry, and from South London and Maudsley National Health Service (NHS) Foundation Trust.

Figures

Figure 1.
Figure 1.
Participant flow. Note. DSM-5 = Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition; EQ-5D-5L = 5-level 5-dimensions EuroQol questionnaire; WPAI:GH = Work Productivity and Activity Impairment Questionnaire: General Health; ADHD-RS-IV = ADHD Rating Scale-IV. aPresented as a checklist: Asperger’s syndrome, autism, schizophrenia, psychosis, severe depression/mania, drug addiction, severe anxiety disorder, obsessive compulsive disorder, none of the above. bFor example, incorrect telephone number provided, participant did not respond when called on several occasions.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Able S. L., Haynes V., Hong J. (2014). Diagnosis, treatment, and burden of illness among adults with attention-deficit/hyperactivity disorder in Europe. Pragmatic and Observational Research, 5, 21-33. doi:10.2147/POR.S64348 - DOI - PMC - PubMed
    1. Adler L. A., Dirks B., Deas P., Raychaudhuri A., Dauphin M., Saylor K., Weisler R. (2013). Self-reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: A randomized, double-blind, multicenter, placebo-controlled, parallel-group study. BMC Psychiatry, 13, Article 253. doi:10.1186/1471-244X-13-253 - DOI - PMC - PubMed
    1. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author.
    1. American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing.
    1. Asherson P., Manor I., Huss M. (2014). Attention-deficit/hyperactivity disorder in adults: Update on clinical presentation and care. Neuropsychiatry, 4, 109-128. doi:10.2217/npy.14.16 - DOI

LinkOut - more resources